Table 4.
Relative risk of second primary cancer by type of first primary cancer and time period
| 1981–1989 | 1990–1999 | 2000–2009 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First primary cancer | O | E | SIR | 95%CI | O | E | SIR | 95%CI | O | E | SIR | 95%CI |
| Oral Cavity & Pharynx | 385 | 115 | 3.36 | (2.89–3.82) | 681 | 190 | 3.58 | (3.21–3.95) | 707 | 210 | 3.37 | (3.05–3.70) |
| Oesophagus | 32 | 11 | 2.93 | (1.79–4.08) | 79 | 31 | 2.54 | (1.93–3.15) | 97 | 50 | 1.95 | (1.52–2.38) |
| Stomach | 117 | 100 | 1.18 | (0.90–1.45) | 165 | 134 | 1.24 | (0.98–1.49) | 132 | 112 | 1.18 | (0.92–1.44) |
| Colorectal | 761 | 628 | 1.22 | (1.01–1.43) | 1183 | 1028 | 1.16 | (0.96–1.36) | 1339 | 1137 | 1.18 | (1.00–1.37) |
| Liver & Intrahepatic Bile Ducts | 9 | 5 | 1.79 | (0.35–3.23) | 25 | 22 | 1.12 | (0.62–1.63) | 72 | 52 | 1.37 | (1.03–1.72) |
| Pancreas | 15 | 11 | 1.34 | (0.53–2.15) | 22 | 23 | 0.98 | (0.50–1.45) | 42 | 37 | 1.14 | (0.75–1.53) |
| Larynx | 170 | 73 | 2.32 | (1.92–2.71) | 247 | 94 | 2.63 | (2.27–3.00) | 253 | 89 | 2.83 | (2.44–3.23) |
| Lung | 291 | 171 | 1.70 | (1.49–1.91) | 433 | 266 | 1.63 | (1.46–1.80) | 530 | 325 | 1.63 | (1.47–1.79) |
| Skin Melanoma | 264 | 212 | 1.25 | (1.05–1.44) | 536 | 441 | 1.22 | (1.05–1.39) | 709 | 593 | 1.20 | (1.04–1.36) |
| Breast female | 721 | 756 | 0.96 | (0.81–1.10) | 1205 | 1301 | 0.93 | (0.81–1.05) | 1435 | 1516 | 0.95 | (0.85–1.05) |
| Cervix Uteri | 97 | 57 | 1.71 | (1.34–2.08) | 86 | 61 | 1.42 | (1.08–1.75) | 65 | 40 | 1.63 | (1.18–2.07) |
| Corpus Uteri & NOS | 197 | 193 | 1.02 | (0.86–1.19) | 285 | 251 | 1.14 | (0.96–1.31) | 309 | 243 | 1.27 | (1.08–1.47) |
| Ovary | 57 | 48 | 1.18 | (0.84–1.52) | 100 | 78 | 1.28 | (1.00–1.56) | 70 | 81 | 0.86 | (0.64–1.09) |
| Prostate | 608 | 858 | 0.71 | (0.59–0.84) | 1544 | 2203 | 0.70 | (0.60–0.81) | 2487 | 3137 | 0.79 | (0.72–0.87) |
| Testis | 31 | 22 | 1.43 | (0.86–1.99) | 54 | 38 | 1.43 | (1.01–1.85) | 55 | 37 | 1.49 | (1.06–1.92) |
| Kidney | 123 | 95 | 1.29 | (1.03–1.55) | 207 | 186 | 1.11 | (0.94–1.29) | 296 | 197 | 1.50 | (1.28–1.72) |
| Bladder | 328 | 242 | 1.36 | (1.14–1.58) | 514 | 352 | 1.47 | (1.22–1.71) | 470 | 277 | 1.70 | (1.43–1.98) |
| Brain & Central Nerves | 15 | 10 | 1.43 | (0.58–2.28) | 24 | 22 | 1.11 | (0.60–1.62) | 39 | 27 | 1.43 | (0.93–1.93) |
| Thyroid | 58 | 48 | 1.22 | (0.87–1.57) | 102 | 76 | 1.35 | (1.06–1.64) | 136 | 95 | 1.44 | (1.18–1.70) |
| Hodgkin Lymphoma | 41 | 17 | 2.40 | (1.58–3.21) | 59 | 26 | 2.27 | (1.63–2.90) | 77 | 29 | 2.63 | (1.99–3.27) |
| Non Hodgkin Lymphoma | 185 | 138 | 1.34 | (1.10–1.59) | 347 | 265 | 1.31 | (1.13–1.50) | 444 | 318 | 1.40 | (1.21–1.59) |
| Multiple Myeloma | 58 | 45 | 1.28 | (0.91–1.66) | 83 | 77 | 1.08 | (0.81–1.35) | 116 | 103 | 1.12 | (0.89–1.36) |
| Leukaemia | 167 | 106 | 1.58 | (1.27–1.89) | 246 | 168 | 1.47 | (1.21–1.73) | 327 | 206 | 1.59 | (1.35–1.84) |
| All Cancers | 5052 | 4172 | 1.21 | (1.07–1.36) | 8752 | 7679 | 1.14 | (1.00–1.28) | 10,837 | 9308 | 1.17 | (1.05–1.28) |
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals